C. Mahan

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Charles E. Mahan, C E Mahan, Charles E Mahan, Charles Mahan, C. E. Mahan
Publication record
46 papers · 1,253 citations · H-index 17

PAPERS

Cost‐of‐Illness Analysis of Long‐Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry
202229 citationsauthor #7
Cost-of-illness analysis of long-term healthcare resource utilization and disease burden in patients with pulmonary embolism: insights from the PREFER in VTE registry
20220 citationsauthor #4
Abstracts for the 38th Annual Emergencies in Medicine Conference
20210 citationsauthor #17
Reply to “Key Points to Consider When Evaluating Andexxa for Formulary Addition”
20201 citationsauthor #1
64 Health Care Costs in Direct-acting Oral Anticoagulant Major Bleeding Treated with 4-factor Prothrombin Complex Concentrate and Other Agents
20200 citationsauthor #2
Potential Drug Interactions between Recombinant Interleukin-2 and Direct Oral Anticoagulants: Indirect Evidence from In Vivo Animal Studies
20201 citationsauthor #4
Extended thromboprophylaxis in the acutely ill medical patient after hospitalization – a paradigm shift in post-discharge thromboprophylaxis
20189 citationsauthor #1
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
201824 citationsauthor #4
Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants
201722 citationsauthor #2
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
201737 citationsauthor #3
Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism.
20177 citationsauthor #3
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
201756 citationsauthor #5
Venous thromboembolism: role of pharmacists and managed care considerations.
20174 citationsauthor #2
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
2016314 citationsauthor #2
Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory
201616 citationsauthor #6
Cost-of-illness model for venous thromboembolism.
201619 citationsauthor #1
European Union-28: An annualised cost-of-illness model for venous thromboembolism
2015109 citationsauthor #5
All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients
20152 citationsauthor #1
Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment
20159 citationsauthor #1
External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR)
201483 citationsauthor #1
A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents
201413 citationsauthor #1
Stroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction
201415 citationsauthor #2
Thrombophilia Issue.
20141 citationsauthor #1
The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation
20137 citationsauthor #4
Identifying, monitoring and reducing preventable major bleeds in the hospital setting
20133 citationsauthor #3
Antithrombotic Medication Use and Bleeding Risk in Medically Ill Patients After Hospitalization
201310 citationsauthor #1
Venous Thromboembolism Prevention in Hospitalized Medical and Surgical Patients
20130 citationsauthor #1
Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population.
201356 citationsauthor #1
Postdischarge mortality risk and risk factors for mortality in acutely ill medical patients following hospitalization
20130 citationsauthor #1
Renaissance of Aspirin for the Primary and Secondary Prevention of Venous Thromboembolism
20130 citationsauthor #6
Venous Thromboembolism Pharmacy Intervention Management Program With an Active, Multifaceted Approach Reduces Preventable Venous Thromboembolism and Increases Appropriate Prophylaxis
201225 citationsauthor #1
Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates
2012165 citationsauthor #1
PCV38 Venous Thromboembolism: A Refined United States Cost Model with Long Term Attack Rates
20120 citationsauthor #4
ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients.
201213 citationsauthor #1
Improving prevention and treatment of venous thromboembolism: clinical trial results
20125 citationsauthor #1
Performance of New Anticoagulants for Thromboprophylaxis in Patients Undergoing Hip and Knee Replacement Surgery
20125 citationsauthor #1
Regulatory, policy and quality update for venous thromboembolism and stroke in United States hospitals.
20129 citationsauthor #1
Venous Thromboembolism: A United States Cost Model for a Preventable and Costly Adverse Event,
20110 citationsauthor #1
New antithrombotics: the impact on global health care.
201123 citationsauthor #1
Venous Thromboembolism Validation Study of the IMPROVE Risk Assessment Models in the Medical Patient (VTE-VALOURR),
20111 citationsauthor #1
Long-term attack rates, as compared with incidence rates, may provide improved cost-estimates in venous thromboembolism. A reply to S. D. Grosse
20111 citationsauthor #1
Prevention of Venous Thromboembolism in Medical Patients
20111 citationsauthor #2
Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event
201177 citationsauthor #1
Venous Thromboembolism Prevention: A Systematic Review of Methods to Improve Prophylaxis and Decrease Events in the Hospitalized Patient
201045 citationsauthor #1
Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing
201018 citationsauthor #1
Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives.
200919 citationsauthor #2

TIMELINE

2009 19 citations

2010 63 citations

2011 103 citations

2012 222 citations

2013 76 citations

2014 112 citations

2015 120 citations

2016 349 citations

2017 126 citations

2018 33 citations

2020 2 citations

2021 0 citations

2022 29 citations

C. Mahan

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT